“With this study, we’ve found a way to potentially harness microglia themselves to treat those diseases,” said Mathew Blurton-Jones of UCI (clockwise from upper left), pictured with Jean Paul Chadarevian of UCI, and Frederick “Chris” Bennett and Sonia Lombroso of Penn.
Combating Alzheimer’s and other neurodegenerative diseases by inserting healthy new immune cells into the brain has taken a leap toward reality.
Neuroscientists at the University of California, Irvine and the University of Pennsylvania have found a way to safely thwart the brain’s resistance to them, vaulting a key hurdle in the quest.
Their discovery about brain cells called microglia heralds myriad possibilities for treating and even preventing neurodegenerative disorders. The team’s paper appears in the Journal of Experimental Medicine.
When microglia are healthy, they serve as the central nervous system’s resident front-line disease warriors. “However, there is overwhelming evidence that they can become dysfunctional in many neurological conditions,” said Mathew Blurton-Jones, UCI professor of neurobiology & behavior and study co-lead author. “Until recently, scientists have mainly been looking at the mechanisms that drive microglial dysfunction and trying to find drugs to change their activity. But with this study, we’ve found a way to potentially harness microglia themselves to treat those diseases.”
Frederick “Chris” Bennett, assistant professor of psychiatry at Penn and co-lead author, added: “There is an obstacle because once our own microglia develop in the location where they are supposed to be in our brains, they don’t give up that space. They block the ability to deliver new cells that would take their place. If you want to insert donor microglia, you have to deplete the host microglia to open up room.”
Bennett and his laboratory partnered with Blurton-Jones and his lab on the project.
Microglia depend on signaling by a protein on their surface called CSF1R for their survival. The FDA-approved cancer drug pexidartinib has been found to block that signaling, killing them. This process would seem to offer a way to clear space in the brain to insert healthy donor microglia. However, there is a dilemma – unless the pexidartinib is stopped before the donor microglia are added, it will eliminate them, too. But once the drug is terminated, the host microglia regenerate too fast to effectively put in the donor cells.
This quandary has challenged efforts to treat people with certain rare and severe neurologic conditions. One is Krabbe disease, in which the body’s cells can’t digest certain fats that are highly abundant in the brain. Currently, clinicians use bone marrow transplantation and chemotherapy to try to introduce new immune cells similar to microglia into the brain. But this approach can be toxic and must be carried out before Krabbe symptoms manifest.
“Our team believed that if we could overcome the brain’s resistance to accepting new microglia, we could successfully transplant them into patients using a safer, more effective process in order to target a great number of diseases,” said co-first author Sonia Lombroso, a Penn Ph.D. student and member of the Bennett Lab. “We decided to investigate whether we could make the donor microglia resistant to the drug that eliminates their host counterparts.”
The researchers used CRISPR gene-editing technology to create one amino acid mutation, known as G795A, which they introduced into donor microglia produced from human stem cells or a mouse microglial cell line. Then they injected the donor microglia into humanized rodent models while administering pexidartinib, with exciting results.
“We discovered that this one small mutation caused the donor microglia to resist the drug and thrive, while the host microglia continued to die off,” said co-first author Jean Paul Chadarevian, a UCI Ph.D. student who is a member of the Blurton-Jones Lab. “This finding could lead to many options for developing new microglial-based treatments. Pexidartinib is already approved for clinical use and appears to be relatively well tolerated by patients.”
Approaches could range from fighting disease by replacing dysfunctional microglia with healthy ones to designing microglia that can recognize imminent threats and strike against them with therapeutic proteins before they cause harm.
The UCI-Penn team believes treatments based on this kind of microglial method could be developed within a decade. Their next investigations include studying in rodent models how to use the approach to attack the brain plaques associated with Alzheimer’s and to counter Krabbe and other similar diseases.
Original Article: Study finds how our brains turn into smarter disease fighters
The Latest Updates from Bing News
Go deeper with Bing News on:
Inserting healthy immune cells into the brain
- Immune System News
Converting Brain Immune Cells Into Neurons Helps Mice Recover After Stroke Oct. 18, 2023 — Researchers have discovered that turning brain immune cells into neurons successfully restores brain ...
- Combined cytotoxic and immune-stimulatory gene therapy for glioma
Comprehending the cellular localisation enhances the precision of region delineation and affords more profound insights into the mechanisms governing immune cell interactions with tumour cells, as ...
- Immune receptor protein linked to healthy aging and lifespan in mice
Life expectancy and healthy aging in mice can be determined by a protein present in some cells of the immune ... the dysfunction of the CD300f immune receptor on brain ageing, in particular ...
- This boy was born without an immune system. Gene therapy rebuilt it.
TUBA CITY, Ariz. - Hataałii Tiisyatonii "HT" Begay, a Native American boy who is Diné, or Navajo, rolls toy trucks around in the dirt. He chases chickens into their coop. He pauses to watch his dad ...
- Immune Health Is All About Balance – An Immunologist Explains Why Both Too Strong And Too Weak An Immune Response Can Lead To Illness
In reality, vaccines are the only safe and effective tool beyond healthy lifestyle behaviors to support your immune system. Vaccines contain harmless forms of pathogens that help to train your immune ...
Go deeper with Bing News on:
- Use of an Olmesartan Medoxomil-Based Treatment Algorithm for Hypertension Control
This study assessed the effectiveness of an antihypertensive treatment algorithm with olmesartan medoxomil as the initial agent. This was a 24-week, open-label trial in patients (N=201 ...
- Cutting-edge antibody therapy firm, AbCellera, to lay off 10 per cent of workforce
The Vancouver-based company that helped develop the first antibody therapy treatment for COVID-19 has announced layoffs amounting to 10 per cent of its workforce. AbCellera Biologics Inc.
- First CRISPR Treatment Approval
The UK has just given regulatory approval to Casgevy (exagamglogene autotemcel) for the treatment of sickle cell disease and transfusion dependent beta-thalassemia (TDT). This is a significant ...
- Mentalization-Based Therapy
Mentalization-based therapy can be an effective treatment for increasing the capacity to mentalize in people with borderline personality disorder, antisocial personality, addiction, eating ...
- Treatment for COVID-19
Treatment is available for COVID-19 to prevent severe illness in people who have symptoms and are at higher risk. To be effective, you need to begin treatment within days of your symptoms starting.